OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients with ATTR Amyloidosis - OverTTuRe

Study identifier:D8450R00004

ClinicalTrials.gov identifier:NCT06355934

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients with ATTR amyloidosis

Medical condition

ATTR amyloidosis

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

55000

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 21 Aug 2023
Estimated Primary Completion Date: 30 Sept 2026
Estimated Study Completion Date: 30 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria